drugset / Trial / NCT06587347

Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

NCT06587347

Phase 2/3 Not yet recruiting 302 enrolled Capital Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

A prospective, multicenter, randomized, controlled, open-label, blinded endpoint trial to evaluate the safety and efficacy of intravenous administration of tirofiban for preventing early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.

Timeline

Start
2024-11-20
Primary completion
2026-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirofiban Other / unclassified 0.1 ug/kg Intravenous
Subject Tirofiban Other / unclassified 0.15 ug/kg Intravenous

Indications